Jingjing Zhou, Yuxin Chen, Wei Liu, Chao Wang, Lei Liu, Wei Geng, Linqing Chai, Dong Yang, Hongji Dai, Haixin Li, Yanrui Zhao, Kexin Chen, Hong Zheng, Lian Li
{"title":"Identification of DNA methylation based prognostic subtype and signature in epithelial ovarian cancer.","authors":"Jingjing Zhou, Yuxin Chen, Wei Liu, Chao Wang, Lei Liu, Wei Geng, Linqing Chai, Dong Yang, Hongji Dai, Haixin Li, Yanrui Zhao, Kexin Chen, Hong Zheng, Lian Li","doi":"10.1007/s00439-025-02808-z","DOIUrl":null,"url":null,"abstract":"<p><p>DNA methylation plays a crucial role in the development and progression of cancer and has been utilized for subtyping various tumors. This study focused on classifying epithelial ovarian cancer (EOC) based on DNA methylation and characterizing the subtypes through an integrated analysis of genomic, transcriptomic, and clinical data. We performed genome-wide DNA methylation profiling on 137 EOC tumor tissues using Infinium MethylationEPIC array and four methylation subtypes (MS1-MS4) were identified by non-negative matrix factorization (NMF) approach, showing significant differences in prognosis (P = 2.413 × 10⁻⁹). The MS1 group showed the best prognosis and the most favorable response to paclitaxel in combination with platinum-based chemotherapy. MS2 exhibited a gene expression pattern of relatively high immune cell infiltration and MS3 had a gene expression pattern associated with metabolic related pathway with a moderate prognosis. In contrast, MS4 had the poorest prognosis and was marked by the highest methylation levels among the four subtypes. A four-differential methylation position (DMP) signature was constructed for prognosis prediction and nomogram was also developed for enhancing clinical utility. Together, this study identified a novel molecular subtype for EOC, elucidating the heterogeneity of EOC from an epigenetic perspective and providing a new strategy for personalized treatment options for EOC patients.</p>","PeriodicalId":13175,"journal":{"name":"Human Genetics","volume":"145 1","pages":"6"},"PeriodicalIF":3.4000,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s00439-025-02808-z","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
DNA methylation plays a crucial role in the development and progression of cancer and has been utilized for subtyping various tumors. This study focused on classifying epithelial ovarian cancer (EOC) based on DNA methylation and characterizing the subtypes through an integrated analysis of genomic, transcriptomic, and clinical data. We performed genome-wide DNA methylation profiling on 137 EOC tumor tissues using Infinium MethylationEPIC array and four methylation subtypes (MS1-MS4) were identified by non-negative matrix factorization (NMF) approach, showing significant differences in prognosis (P = 2.413 × 10⁻⁹). The MS1 group showed the best prognosis and the most favorable response to paclitaxel in combination with platinum-based chemotherapy. MS2 exhibited a gene expression pattern of relatively high immune cell infiltration and MS3 had a gene expression pattern associated with metabolic related pathway with a moderate prognosis. In contrast, MS4 had the poorest prognosis and was marked by the highest methylation levels among the four subtypes. A four-differential methylation position (DMP) signature was constructed for prognosis prediction and nomogram was also developed for enhancing clinical utility. Together, this study identified a novel molecular subtype for EOC, elucidating the heterogeneity of EOC from an epigenetic perspective and providing a new strategy for personalized treatment options for EOC patients.
期刊介绍：
Human Genetics is a monthly journal publishing original and timely articles on all aspects of human genetics. The Journal particularly welcomes articles in the areas of Behavioral genetics, Bioinformatics, Cancer genetics and genomics, Cytogenetics, Developmental genetics, Disease association studies, Dysmorphology, ELSI (ethical, legal and social issues), Evolutionary genetics, Gene expression, Gene structure and organization, Genetics of complex diseases and epistatic interactions, Genetic epidemiology, Genome biology, Genome structure and organization, Genotype-phenotype relationships, Human Genomics, Immunogenetics and genomics, Linkage analysis and genetic mapping, Methods in Statistical Genetics, Molecular diagnostics, Mutation detection and analysis, Neurogenetics, Physical mapping and Population Genetics. Articles reporting animal models relevant to human biology or disease are also welcome. Preference will be given to those articles which address clinically relevant questions or which provide new insights into human biology.
Unless reporting entirely novel and unusual aspects of a topic, clinical case reports, cytogenetic case reports, papers on descriptive population genetics, articles dealing with the frequency of polymorphisms or additional mutations within genes in which numerous lesions have already been described, and papers that report meta-analyses of previously published datasets will normally not be accepted.
The Journal typically will not consider for publication manuscripts that report merely the isolation, map position, structure, and tissue expression profile of a gene of unknown function unless the gene is of particular interest or is a candidate gene involved in a human trait or disorder.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
